Cargando…

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN

BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamagnan, Gilles, Barret, Olivier, Alagille, David, Carroll, Vincent, Madonia, Jennifer, Constantinescu, Cristian, SanDiego, Christine, Papin, Caroline, Morley, Thomas, Russell, David, McCarthy, Timothy, Zhang, Lei, Gray, David, Villalobos, Anna, Lee, Chewah, Chen, Jianqing, Seibyl, John, Marek, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888516/
http://dx.doi.org/10.1093/schbul/sby016.432
_version_ 1783312540719120384
author Tamagnan, Gilles
Barret, Olivier
Alagille, David
Carroll, Vincent
Madonia, Jennifer
Constantinescu, Cristian
SanDiego, Christine
Papin, Caroline
Morley, Thomas
Russell, David
McCarthy, Timothy
Zhang, Lei
Gray, David
Villalobos, Anna
Lee, Chewah
Chen, Jianqing
Seibyl, John
Marek, Kenneth
author_facet Tamagnan, Gilles
Barret, Olivier
Alagille, David
Carroll, Vincent
Madonia, Jennifer
Constantinescu, Cristian
SanDiego, Christine
Papin, Caroline
Morley, Thomas
Russell, David
McCarthy, Timothy
Zhang, Lei
Gray, David
Villalobos, Anna
Lee, Chewah
Chen, Jianqing
Seibyl, John
Marek, Kenneth
author_sort Tamagnan, Gilles
collection PubMed
description BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for the D1 receptors labeled with 18F with relevance in clinical studies. We report the evaluation in non-human primates of [18F]MNI-968 (PF-06730110), a novel PET radiotracer of the D1 receptors METHODS: Four brain PET studies, 2 baselines and 2 blockade studies using PF-2562, a D1 partial agonist compound, were conducted for 90 min in two rhesus monkeys with [18F]MNI-968 (169 ± 31 MBq). [18F]PF-06730110 was administered at the same dose level for both monkeys as a bolus followed by a 2-hour infusion, with [18F]MNI-968 administered 30 min into the infusion. Additionally, six brain PET studies were conducted over 180 min (317 ± 49 MBq) in 6 healthy human volunteers (3 test/retest and 3 test). PET data were modeled with 2-tissue compartmental model (2T), Logan graphical analysis (LGA), and non-invasive Logan graphical analysis (NI-LGA) with cerebellar cortex as reference region to estimate total distribution volume VT, and binding potential BPND. For the blockade studies in rhesus monkeys, occupancy was estimated from BPND at baseline and post blockade. RESULTS: In rhesus monkeys, [18F]MNI-968 (PF-06730110), penetrated the brain with a peak whole-brain uptake up to ~3% of the injected dose at ~ 6 min post injection and showed a fast washout. The highest signal was found in the caudate, putamen, with moderate extrastriatal uptake. The lowest signal was in the cerebellum. BPND values were up to ~1.4 in the putamen. All three quantification methods (2T, LGA and NI-LGA) were in excellent agreement, with a similar estimated D1 receptors occupancy of PF-06730110 of ~40% for both monkeys in the caudate and putamen. In human, [18F]MNI-968 kinetics appeared to be faster compared to non-human primates, with a BPND in the putamen of ~0.8. Initial measurement of test-retest reproducibility was ≤ 7% for BPND in the striatal regions. DISCUSSION: Our work showed that [18F]MNI-968 ([18F]PF-06730110), is a promising agonist PET radiotracer for imaging D1agnist receptors that can be quantified non-invasively. Studies are currently ongoing both in non-human and human primates to further characterize the tracer.
format Online
Article
Text
id pubmed-5888516
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58885162018-04-11 T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN Tamagnan, Gilles Barret, Olivier Alagille, David Carroll, Vincent Madonia, Jennifer Constantinescu, Cristian SanDiego, Christine Papin, Caroline Morley, Thomas Russell, David McCarthy, Timothy Zhang, Lei Gray, David Villalobos, Anna Lee, Chewah Chen, Jianqing Seibyl, John Marek, Kenneth Schizophr Bull Abstracts BACKGROUND: D1 receptors, which couple to inhibitory G-proteins, have been shown to regulate neuronal growth and development, mediate some behavioral responses. Its function has been shown to be altered in both neurologic and psychiatric disorders. To date, there is a lack of agonist PET tracers for the D1 receptors labeled with 18F with relevance in clinical studies. We report the evaluation in non-human primates of [18F]MNI-968 (PF-06730110), a novel PET radiotracer of the D1 receptors METHODS: Four brain PET studies, 2 baselines and 2 blockade studies using PF-2562, a D1 partial agonist compound, were conducted for 90 min in two rhesus monkeys with [18F]MNI-968 (169 ± 31 MBq). [18F]PF-06730110 was administered at the same dose level for both monkeys as a bolus followed by a 2-hour infusion, with [18F]MNI-968 administered 30 min into the infusion. Additionally, six brain PET studies were conducted over 180 min (317 ± 49 MBq) in 6 healthy human volunteers (3 test/retest and 3 test). PET data were modeled with 2-tissue compartmental model (2T), Logan graphical analysis (LGA), and non-invasive Logan graphical analysis (NI-LGA) with cerebellar cortex as reference region to estimate total distribution volume VT, and binding potential BPND. For the blockade studies in rhesus monkeys, occupancy was estimated from BPND at baseline and post blockade. RESULTS: In rhesus monkeys, [18F]MNI-968 (PF-06730110), penetrated the brain with a peak whole-brain uptake up to ~3% of the injected dose at ~ 6 min post injection and showed a fast washout. The highest signal was found in the caudate, putamen, with moderate extrastriatal uptake. The lowest signal was in the cerebellum. BPND values were up to ~1.4 in the putamen. All three quantification methods (2T, LGA and NI-LGA) were in excellent agreement, with a similar estimated D1 receptors occupancy of PF-06730110 of ~40% for both monkeys in the caudate and putamen. In human, [18F]MNI-968 kinetics appeared to be faster compared to non-human primates, with a BPND in the putamen of ~0.8. Initial measurement of test-retest reproducibility was ≤ 7% for BPND in the striatal regions. DISCUSSION: Our work showed that [18F]MNI-968 ([18F]PF-06730110), is a promising agonist PET radiotracer for imaging D1agnist receptors that can be quantified non-invasively. Studies are currently ongoing both in non-human and human primates to further characterize the tracer. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888516/ http://dx.doi.org/10.1093/schbul/sby016.432 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Tamagnan, Gilles
Barret, Olivier
Alagille, David
Carroll, Vincent
Madonia, Jennifer
Constantinescu, Cristian
SanDiego, Christine
Papin, Caroline
Morley, Thomas
Russell, David
McCarthy, Timothy
Zhang, Lei
Gray, David
Villalobos, Anna
Lee, Chewah
Chen, Jianqing
Seibyl, John
Marek, Kenneth
T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title_full T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title_fullStr T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title_full_unstemmed T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title_short T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
title_sort t156. in vivo characterization of the first agonist dopamine d1 receptors pet imaging tracer [18f]mni-968 in human
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888516/
http://dx.doi.org/10.1093/schbul/sby016.432
work_keys_str_mv AT tamagnangilles t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT barretolivier t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT alagilledavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT carrollvincent t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT madoniajennifer t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT constantinescucristian t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT sandiegochristine t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT papincaroline t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT morleythomas t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT russelldavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT mccarthytimothy t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT zhanglei t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT graydavid t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT villalobosanna t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT leechewah t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT chenjianqing t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT seibyljohn t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman
AT marekkenneth t156invivocharacterizationofthefirstagonistdopamined1receptorspetimagingtracer18fmni968inhuman